Peter Gottlieb
, Professor · University of Colorado School of Medicine
Credentials: · · · ·
History
Research
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
The Journal of Experimental Medicine · 2006 · 2,136 citations
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
New England Journal of Medicine · 2019 · 918 citations
Diabetes Care · 2015 · 904 citations
31 papers
23 papers · 1 as a fellow
- CG
23 papers
- GE
22 papers
22 papers
21 papers · 1 as a fellow
21 papers
21 papers
Grants
- 2009–2020
TrialNet: Diabetes Type 1 Prevention
National Institute of Diabetes and Digestive and Kidney Diseases · U01
Contact PI · $5.8M · University of Colorado Denver
- 2001–2008
TrialNet: Diabetes Type 1 Prevention Trial
National Institute of Diabetes and Digestive and Kidney Diseases · U01
Contact PI · $1.6M · University of Colorado Denver
- 2004–2008
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $19.9K · University of Colorado Denver
- 2005–2008
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $137.9K · University of Colorado Denver
Clinical trials
- 2020–2025
Principal investigator · Completed · Phase 1
University of Colorado, Denver
- 2010–2016
The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes
Principal investigator · Completed · Phase 1
University of Colorado, Denver
- 2006–2011
Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus
Study chair · Completed · Phase 1
Bayhill Therapeutics